47 results about "Ovarian cancer cell line" patented technology

The invention relates to a TOP medicament resistant cell line human ovarian cancer, with a accession number of CGMCC No 1217, which is selecting human ovarian cancer cell line as parental cell, putting the cell into RPMI1640 culture medium containing 15% calf serum, putting into incubator with 5% CO2 and 37 DEG C to culture; acquiring cells in logarithmic growth phase, counting after digesting with 0.25% pancreatin, inoculating 5*105 / ml into culture bottle according to amount of 5ml in each bottle, when cells adheres to wall after 24 hours, reacting for 2 hours with a TOPfinal content of 2160ng / ml, discarding culture medium, washing by phosphate buffer for 3 times, replacing fresh culture medium, second impulsing after growing is resumed, and repeatedly operating, until it is impulsed with medicament for 13 times. The cell line is constructed for 10 months, medicament resistance of cell is 10.67 per cell, P<0.01 comparing with sensitive cell, has cross resistanceto mitoxantrone, camptothecin, vincristine besides resistance to TOP.

The invention discloses an application of siRNA of long non-coding RNA (long non-coding RNA, lncRNA) SMAD5-AS1 in the treatment of ovarian cancer. The present invention designs and synthesizes an siRNA sequence that specifically targets and inhibits SMAD5-AS1, and transfects it into ovarian cancer cell lines. It is confirmed that inhibiting the expression of SMAD5-AS1 can significantly inhibit the proliferation, migration and invasion of ovarian cancer cells. The invention provides a new method and a new drug development direction for the treatment of ovarian cancer.

The invention relates to a multidrug-resistant ovarian cancer cell line induced and established by triptolide and use thereof. The cell line is named SKOV3 / TPL, and the microorganism preservation number is CGMCC No. 10306. In the parental cells, the concentration of Triptolide (TPL), a monomeric extract of the traditional Chinese medicine Triptolide, was gradually increased from 10nM to 400nM, and the multidrug-resistant ovarian cancer cell line SKOV3 / TPL was established. The multidrug-resistant ovarian cancer cell line SKOV3 / TPL can stably grow, passage and recover in 400nM TPL, and its resistance index (RI) to TPL is 50.95. ‑FU, Ara‑C, GEM, VP‑16, MMC, ADM, MIT, TAX, VCR have cross-resistance. The establishment of the multidrug-resistant ovarian cancer cell line of the present invention provides a drug-resistant tumor cell model for tumor-related research, and the action mechanism of the drug can be studied by comparing its genetic difference with the parental cell.

The invention discloses a human PARD6A gene expression inhibiting small-interference ribonucleic acid sequence and a use thereof in resisting proliferation and metastasis of ovarian cancer, and belongs to the technical fields of targeted gene medicine research and development and cell biology. Two pairs of siRNAs both can be bonded with the mRNA of the PARD6A gene in an ovarian cancer cell line to effectively interfere with transcription thereof before translation such that the proliferation activity and adsorption capability of cells are inhibited, thus achieving the purposes of controlling the growth and metastasis of ovarian cancer cells and treating ovarian cancer. The two pairs of siRNAs of the human PARD6A gene expression inhibiting small-interference ribonucleic acid sequence is promising in preparation of anti-ovarian caner medicines having high efficiency, specificity, and low side effect.

The present invention relates to treatment of ovarian cancer by reducing pyridoxine phosphate oxidase (PNPO). The present invention has confirmed through experiments that reducing PNPO can inhibit the proliferation, migration and invasion of ovarian cancer cell lines, and lead to cell cycle G2 / M phase arrest, suggesting that PNPO is a potential new target for the treatment of ovarian cancer, which can target Patients with high expression of PNPO in ovarian cancer can be treated by reducing the expression of PNPO to achieve the purpose of treatment, and at the same time, it is beneficial to further study the mechanism of occurrence and development of ovarian cancer.

The invention discloses an evodiamine copper salt compound with anti-tumor activity and a synthesis method thereof. The structure of the evodiamine copper salt compound has obvious inhibitory effect on ovarian cancer cell line Skov3, showing potential medicinal use value, and is expected to be used as a metal antitumor drug. It belongs to the field of medical technology.

The invention discloses tetrahydropyridinopyran-monoclonal antibody CD14 conjugates with anti-tumor activity and a preparation method and use thereof. The structure of the conjugate is represented by a formula (II). Under the action of dicyclohexylcarbodiimide (DCC) serving as a condensing agent, an amino acid residue on the carbon terminal of a CD14 monoclonal molecule is bonded with an amino on a pyran ring in a tetrahydropyridinopyran derivative to form a monoclonal antibody conjugate CD14-TPP of the formula (II). CD14-TPP can effectively inhibit the proliferation of a human erythroleukemia cell line K562, an ovarian cancer cell line MDR-MB-231 and a liver cancer cell line SMMC-7721 with an IC50 value much lower than 5-fluorouracil (5Fu) which is a conventional chemotherapy medicine. The conjugate of the formula (II) with low toxic effect on normal bone narrow cells of mouse can be used for preparing medicines for treating leukemia, ovarian cancer and liver cancer.

The invention provides the application of human ALKBH1 gene in the preparation of products for diagnosing and / or treating tumors. The present invention finds that the expression level of the ALKBH1 gene is significantly increased by detecting the expression of the ALKBH1 gene in tumor tissues of gastric cancer and liver cancer patients. Compared with the control group, the DNA 6mA modification level, proliferation ability, cell migration rate and cell invasion ability of the liver cancer and ovarian cancer cell lines constructed by constructing ALKBH1 gene overexpression / silencing were significantly changed. The ALKBH1 gene and its expression products are used as markers for diagnosing tumors, making tumor diagnosis more accurate and rapid, and as target genes for preparing tumor drugs, providing new therapeutic targets and therapeutic approaches for treating tumors.

The invention discloses a red hair algae polysaccharide and its preparation method and application. The red hair algae polysaccharide is composed of rhamnose, arabinose, mannose, glucose and galactose, and it is effective against ovarian cancer cell lines A2780, COC1, SKOV3, HO‑8910 and OVCAR3 all have significant inhibitory effects and are expected to be used in the preparation of drugs for treating ovarian cancer.

The invention discloses a genistein derivative and its preparation method and application. The process steps of the invention are: (1) Synthesis of 5-fluorouracil-1-acetic acid: 5-fluorouracil reacts with chloroacetic acid in aqueous alkali solution , generate 5-fluorouracil-1-acetic acid; (2) preparation of genistein derivatives: dissolve 5-fluorouracil-1-acetic acid and genistein in an organic solvent and add a catalyst to react, filter, and dry the filter cake to obtain A new genistein derivative. The derivative of the present invention has good solubility in organic solvents, has good inhibition rate on liver cancer cell HepG2 and ovarian cancer cell line SKOV-3, and is expected to develop a new drug with anti-tumor effect.

The invention belongs to the technical field of medicines and relates to a tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine compound containing a thioether structure and application of the tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine compound as an epidermal growth factor receptor tyrosine kinase inhibitor and a preparation method the tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine compound. The tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine compound containing the thioether structure, pharmaceutically acceptable salt, and a pharmaceutically compatibility acceptable carrier or a diluent are used as the epidermal growth factor receptor tyrosine kinase inhibitor. The structural general formula of the compound is shown in the description, wherein R1 and R2 are shown in the claim and description. The compound provided by the invention is simple and convenient in synthesis method, and suitable for industrial production, and a biological activity test result shows that the compound has the effect of restraining activity of epidermal growth factors, activity of human lung cancer cell line A549, activity of human ovarian cancer cell line SKOV3 and activity of human osteosarcoma cell U2OS-EGFP-4A12G, and is the epidermal growth factor receptor tyrosine kinase inhibitor with an anti-tumor effect.